The nucleotide prodrug CERC‐913 improves mtDNA content in primary hepatocytes from DGUOK‐deficient rats
- 25 December 2020
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (2), 492-501
- https://doi.org/10.1002/jimd.12354
Abstract
Loss‐of‐function mutations in the deoxyguanosine kinase (DGUOK) gene result in a mitochondrial DNA (mtDNA) depletion syndrome. DGUOK plays an important role in converting deoxyribonucleosides to deoxyribonucleoside monophosphates via the salvage pathway for mtDNA synthesis. DGUOK deficiency manifests predominantly in the liver; the most common cause of death is liver failure within the first year of life and no therapeutic options are currently available. in vitro supplementation with deoxyguanosine or deoxyguanosine monophosphate (dGMP) were reported to rescue mtDNA depletion in DGUOK‐deficient, patient‐derived fibroblasts and myoblasts. CERC‐913, a novel ProTide prodrug of dGMP, was designed to bypass defective DGUOK while improving permeability and stability relative to nucleoside monophosphates. To evaluate CERC‐913 for its ability to rescue mtDNA depletion, we developed a primary hepatocyte culture model using liver tissue from DGUOK‐deficient rats. DGUOK knockout rat hepatocyte cultures exhibit severely reduced mtDNA copy number (~10%) relative to wild type by qPCR and mtDNA content remains stable for up to 8 days in culture. CERC‐913 increased mtDNA content in DGUOK‐deficient hepatocytes up to 2.4‐fold after 4 days of treatment in a dose‐dependent fashion, which was significantly more effective than dGMP at similar concentrations. These early results suggest primary hepatocyte culture is a useful model for the study of mtDNA depletion syndromes and that CERC‐913 treatment can improve mtDNA content in this model.This publication has 29 references indexed in Scilit:
- Species Difference of Esterase Expression and Hydrolase Activity in PlasmaJournal of Pharmaceutical Sciences, 2012
- Recessive deoxyguanosine kinase deficiency causes juvenile onset mitochondrial myopathyMolecular Genetics and Metabolism, 2012
- In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletionMolecular Genetics and Metabolism, 2012
- Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661Antiviral Research, 2011
- INX-08189, a Phosphoramidate Prodrug of 6- O -Methyl-2′- C -Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic PropertiesAntimicrobial Agents and Chemotherapy, 2011
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C VirusJournal of Medicinal Chemistry, 2010
- Phosphoramidate ProTides of 2′-C-Methylguanosine as Highly Potent Inhibitors of Hepatitis C Virus. Study of Their in Vitro and in Vivo PropertiesJournal of Medicinal Chemistry, 2010
- In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromesHuman Molecular Genetics, 2009
- Mitochondrial deoxyribonucleotide pools in deoxyguanosine kinase deficiencyMolecular Genetics and Metabolism, 2008
- Mitochondrial DNA depletion and dGK gene mutationsAnnals of Neurology, 2002